TUB-060

TUB-060 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Tubulis for the treatment of solid tumors. The drug is engineered using Tubulis' proprietary ADC technologies, which are designed to create highly stable and homogeneous conjugates with an optimized therapeutic index. While the specific biological target and the nature of the cytotoxic payload remain undisclosed, TUB-060 is intended to selectively deliver a potent cell-killing agent to tumor cells, minimizing off-target effects. It is part of a broader pipeline of next-generation ADCs aimed at addressing limitations in current ADC therapies, such as linker instability and limited payload delivery.